Skip to main content
Knowledge4Policy
Knowledge for policy

Supporting policy with scientific evidence

We mobilise people and resources to create, curate, make sense of and use knowledge to inform policymaking across Europe.

WHO updated list of essential medicines includes key treatments for cancer

The World Health Organisation (WHO) has released the updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer, among others.

  • News | 23 Oct 2025
Celia BURGAZ Celia BURGAZ Cancer Centre
WHO Logo

In the month of September, the World Health Organisation (WHO) released the updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer, as well as diabetes with associated comorbidities such as obesity. Other additions also include medicines for cystic fibrosis, psoriasis, haemophilia and blood-related disorders.

The WHO EML and EMLc include medicines that address the priority health needs of populations. They are updated and published every 2 years and are intended as a guide for countries or regional authorities to adopt or adapt in accordance with local priorities and treatment guidelines for the development and updating of national essential medicines lists. Thus, these lists serve as the basis for public-sector procurement and the supply of medicines, as well as health insurance and reimbursement schemes. These revisions mark the 24th edition of the WHO EML and 10th edition of the EMLc. 

More information and links
Originally Published

23 Oct 2025

Related organisation(s)WHO - World Health Organisation
Knowledge service | MetadataCancer Centre | non-communicable diseases
Digital Europa Thesaurus (DET)cancerpublic health
Related reading
More
Privacy statements, terms and conditions.
You will be directed to the EU Login website where you can login/register as a user. Once connected, your credentials (First name, last name, username, email) will be registered in Knowledge4policy as part of your profile, which will allow you to get involved in all Knowledge4policy communities (help is available).
You are leaving EUROPA

You are about to navigate to an external website. Please note that we are not responsible for its content.